PTH134

PTH134 is an investigational oral formulation of teriparatide, which is the recombinant form of the 1-34 amino acid fragment of human parathyroid hormone. Developed by Novartis, it was designed for the treatment of postmenopausal osteoporosis and osteopenia. The drug functions as an agonist of the parathyroid hormone receptor 1 (PTH1R), stimulating bone formation by increasing osteoblast activity and number. While teriparatide is traditionally administered via subcutaneous injection (e.g., Forsteo/Forteo), PTH134 utilizes oral delivery technology to facilitate gastrointestinal absorption of the peptide. This formulation aims to provide the anabolic benefits of parathyroid hormone therapy with the convenience of oral administration, potentially improving patient compliance in chronic bone density management.

Other names

oral teriparatideoral PTH(1-34)PTH-134PTH134PTH 134